Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

M. Forde, Patrick; E. Chaft, Jamie; N. Smith, Kellie; Anagnostou, Valsamo; R. Cottrell, Tricia; D. Hellmann, Matthew; Zahurak, Marianna; C. Yang, Stephen; R. Jones, David; Broderick, Stephen; J. Battafarano, Richard; J. Velez, Moises; Rekhtman, Natasha; T. Olah, Zachary; Naidoo, Jarushka; A. Marrone, Kristen; Verde, Franco; Guo, Haidan; Zhang, Jiajia; X. Caushi, Justina; Yee Chan, Hok; Sidhom, John-William; B. Scharpf, Robert; R. White, James; Gabrielson, Edward; Wang, Hao; L. Rosner, Gary; W. Rusch, Valerie; D. Wolchok, Jedd; Merghoub, Taha; M. Taube, Janis; E. Velculescu, Victor; L. Topalian, Suzanne; R. Brahmer, Julie; M. Pardoll, Drew

doi:10.1056/nejmoa1716078

Public

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Published in New England Journal of Medicine • Apr 16, 2018

Authors:

Patrick M. Forde

Jamie E. Chaft

Kellie N. Smith

Abstract

BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we ...

Subject

Blockade

Medicine

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!